Discussion of lung adenocarcinoma effectively treated with erlotinib: A case investigation

Yoshitsugu Fujita; Masamichi Mineshita; Hirotaka Kida; Hiroshi Handa; Fuzuki Ishikawa; Masahiro Oshige; Teruomi Miyazawa; Kenji Eguchi; Nobuhiko Seki; Ken Inoue

Discussion of lung adenocarcinoma effectively treated with erlotinib: A case investigation

Yoshitsugu Fujita, Masamichi Mineshita, Hirotaka Kida, Hiroshi Handa, Fuzuki Ishikawa, Masahiro Oshige, Teruomi Miyazawa, Kenji Eguchi, Nobuhiko Seki, Ken Inoue

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: The current reality is that the usage of gefitinib and erlotinib, two molecularly targeted drugs to treat advanced non-small cell lung cancer, has not been clearly delineated. Here, we report a case of lung adenocarcinoma in which the patient developed resistance to gefitinib but later erlotinib therapy proved to be effective. Discussion: Erlotinib is an oral agent and is also beneficial in terms of QOL.

Original language	English
Pages (from-to)	236-237
Number of pages	2
Journal	International Medical Journal
Volume	17
Issue number	3
State	Published - Sep 2010

Keywords

Erlotinib
Lung cancer
Molecularly targeted drug

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{cb731b85b9194b8b90bb56b4cdf19db8,

title = "Discussion of lung adenocarcinoma effectively treated with erlotinib: A case investigation",

abstract = "Introduction: The current reality is that the usage of gefitinib and erlotinib, two molecularly targeted drugs to treat advanced non-small cell lung cancer, has not been clearly delineated. Here, we report a case of lung adenocarcinoma in which the patient developed resistance to gefitinib but later erlotinib therapy proved to be effective. Discussion: Erlotinib is an oral agent and is also beneficial in terms of QOL.",

keywords = "Erlotinib, Lung cancer, Molecularly targeted drug",

author = "Yoshitsugu Fujita and Masamichi Mineshita and Hirotaka Kida and Hiroshi Handa and Fuzuki Ishikawa and Masahiro Oshige and Teruomi Miyazawa and Kenji Eguchi and Nobuhiko Seki and Ken Inoue",

year = "2010",

month = sep,

language = "英語",

volume = "17",

pages = "236--237",

journal = "International Medical Journal",

issn = "1341-2051",

publisher = "Japan International Cultural Exchange Foundation",

number = "3",

}

TY - JOUR

T1 - Discussion of lung adenocarcinoma effectively treated with erlotinib

T2 - A case investigation

AU - Fujita, Yoshitsugu

AU - Mineshita, Masamichi

AU - Kida, Hirotaka

AU - Handa, Hiroshi

AU - Ishikawa, Fuzuki

AU - Oshige, Masahiro

AU - Miyazawa, Teruomi

AU - Eguchi, Kenji

AU - Seki, Nobuhiko

AU - Inoue, Ken

PY - 2010/9

Y1 - 2010/9

N2 - Introduction: The current reality is that the usage of gefitinib and erlotinib, two molecularly targeted drugs to treat advanced non-small cell lung cancer, has not been clearly delineated. Here, we report a case of lung adenocarcinoma in which the patient developed resistance to gefitinib but later erlotinib therapy proved to be effective. Discussion: Erlotinib is an oral agent and is also beneficial in terms of QOL.

AB - Introduction: The current reality is that the usage of gefitinib and erlotinib, two molecularly targeted drugs to treat advanced non-small cell lung cancer, has not been clearly delineated. Here, we report a case of lung adenocarcinoma in which the patient developed resistance to gefitinib but later erlotinib therapy proved to be effective. Discussion: Erlotinib is an oral agent and is also beneficial in terms of QOL.

KW - Erlotinib

KW - Lung cancer

KW - Molecularly targeted drug

UR - http://www.scopus.com/inward/record.url?scp=77957015451&partnerID=8YFLogxK

M3 - 記事

AN - SCOPUS:77957015451

SN - 1341-2051

VL - 17

SP - 236

EP - 237

JO - International Medical Journal

JF - International Medical Journal

IS - 3

ER -

Discussion of lung adenocarcinoma effectively treated with erlotinib: A case investigation

Abstract

Keywords

UN SDGs

Other files and links

Fingerprint

Cite this